These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29184006)

  • 1. Pain improvement in Camurati-Engelmann disease after anti-TNFα therapy.
    Moreira S; Cunha B; Jesus NP; Santos L
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29184006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature.
    Horgan L; Mulrennan S; D'Orsogna L; McLean-Tooke A
    BMC Gastroenterol; 2019 Nov; 19(1):171. PubMed ID: 31675916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
    Thukral C; Cheifetz A; Peppercorn MA
    Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan as a Steroid-Sparing Adjunct in a Patient With Features of Refractory Camurati-Engelmann Disease.
    Agarwal K; Rajan R; Paul J; Cherian KE; Kapoor N; Paul TV
    AACE Clin Case Rep; 2022; 8(2):54-57. PubMed ID: 35415233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
    Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
    Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute severe ulcerative colitis treated with accelerated infliximab induction. Case report].
    Fluxá D; Flores L; Kronberg U; Moreno M; Figueroa C; Ibáñez P; Lubascher J; Simian D; Quera R
    Rev Med Chil; 2017 Aug; 145(8):1083-1088. PubMed ID: 29189869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Management of Ulcerative Colitis.
    Vanga R; Long MD
    Curr Gastroenterol Rep; 2018 Mar; 20(3):12. PubMed ID: 29589185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of denosumab therapy after alendronate treatment for a 66-year-old woman with Camurati-Engelmann disease and osteoporosis: a case report.
    Uehara M; Nakamura Y; Suzuki T; Takahashi J; Kato H
    Mod Rheumatol Case Rep; 2020 Jan; 4(1):131-134. PubMed ID: 33086975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthopedic Manifestations of Type I Camurati-Engelmann Disease.
    Yuldashev AJ; Shin CH; Kim YS; Jang WY; Park MS; Chae JH; Yoo WJ; Choi IH; Kim OH; Cho TJ
    Clin Orthop Surg; 2017 Mar; 9(1):109-115. PubMed ID: 28261436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.
    Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
    Dig Liver Dis; 2002 Sep; 34(9):626-30. PubMed ID: 12405248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for patients with refractory ulcerative colitis.
    Chey WY
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S30-3. PubMed ID: 11380041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan.
    Ayyavoo A; Derraik JG; Cutfield WS; Hofman PL
    J Clin Endocrinol Metab; 2014 Nov; 99(11):3978-82. PubMed ID: 25140400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of a simple ulcer associated with ulcerative colitis that demonstrated a good clinical response to infliximab].
    Kishi M; Sou S; Ishihara H; Terabe H; Yasaka M; Kuhara K; Takeda T; Shimokoube M; Morimitsu Y; Miyazono K
    Nihon Shokakibyo Gakkai Zasshi; 2015; 112(9):1682-8. PubMed ID: 26346358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camurati-Engelmann disease--a rare cause of bone pain.
    Mundra V; Taxel P
    Conn Med; 2012 Jan; 76(1):33-7. PubMed ID: 22372177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for treatment of steroid-refractory ulcerative colitis.
    Actis GC; Bruno M; Pinna-Pintor M; Rossini FP; Rizzetto M
    Dig Liver Dis; 2002 Sep; 34(9):631-4. PubMed ID: 12405249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.